Chen, Oleg
Manig, Friederike
Lehmann, Loreen
Sorour, Nagwa
Löck, Steffen
Yu, Zhanru
Dubrovska, Anna
Baumann, Michael
Kessler, Benedikt M.
Stasyk, Oleh
Kunz-Schughart, Leoni A. http://orcid.org/0000-0003-3912-6594
Funding for this research was provided by:
Deutscher Akademischer Austauschdienst
European Social Fund
State of Saxony/European Social Fund
Technische Universität Dresden
Article History
Received: 25 May 2020
Revised: 19 October 2020
Accepted: 4 November 2020
First Online: 23 November 2020
Compliance with ethical standards
:
: In the past 5 years, Prof. Michael Baumann attended an advisory board meeting of MERCK KGaA (Darmstadt), for which the TU Dresden received a travel grant. He further received funding for his research projects and for educational grants to the TU Dresden by Teutopharma GmbH (2011–2015), IBA (2016), Bayer AG (2016–2018), Merck KGaA (2016–2030), Medipan GmbH (2014–2018). For the German Cancer Research Center (DKFZ, Heidelberg) Dr. Baumann is on the supervisory boards of HI-STEM gGmbH (Heidelberg). Dr. Baumann, as former chair of OncoRay (Dresden) and present CEO and Scientific Chair of the German Cancer Research Center (DKFZ, Heidelberg), was or is responsible for collaborations with a multitude of companies and institutions, worldwide. In this capacity, he has signed/signs contracts for his institute(s) and for the staff for research funding and/or collaborations with industry and academia, worldwide. In this role, he was/is further responsible for commercial technology transfer activities of his institute(s), including patent and other similar IP portfolios. Dr. Baumann confirms that none of the above funding sources were involved in the preparation of this paper. Other authors declare no further competing interests.